STADA and SBP Group launch strategic biosimilars partnership, including a biosimilar to Keytruda - STADA and Sino Biopharmaceutical Limited (SBP Group) subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) enter into an exclusive partnership to ...
Press Release Enzymatica and STADA sign partnership agreement for Germany and Austria - New partnership agreement covers thelaunch and distribution of Enzymatica’s ColdZyme® oral-spray technology in Germany and Austria - Alliance combines Enzymatica’s clinically documented medical device with ...
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
Global Health Centre, The Graduate Institute of International and Development Studies
